Loading...
•
Mar 31, 2021
Glaukos Q1 2021 Earnings Report
Glaukos's net sales increased by 23% to $68.0 million, driven by growth in both Glaucoma and Corneal Health segments. The company reported a gross margin of approximately 76% and a non-GAAP gross margin of approximately 84%.
Key Takeaways
Glaukos Corporation reported a strong start to the year with a 23% increase in net sales, reaching $68.0 million. The growth was fueled by solid performance in both the Glaucoma and Corneal Health segments. The company's gross margin stood at approximately 76%, with a non-GAAP gross margin of approximately 84%.
Net sales grew by 23% to $68.0 million compared to the same period last year.
Glaucoma net sales reached $53.7 million.
Corneal Health net sales were $14.3 million.
Gross margin was approximately 76%, and non-GAAP gross margin was approximately 84%.
Revenue by Segment
Forward Guidance
The company expects the second quarter of 2021 net sales to be in the range of $70 million to $72 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...